Associate Professor
Fox Chase Cancer Center
My primary academic surgical focus is on borderline resectable pancreatic cancer. This has culminated into a rewarding collaborations within the Greenberg Pancreatic Cancer Institute, to which I was named Co-Director in 2019. Within this disease space, surgery is often not the one and all option for treatment. Rather, multidisciplinary care and collaboration with medical and radiation oncologists prove to be a vital component. As such, I have been involved in several national cooperative group clinical trials in pancreas cancer, both looking at utilizing neoadjuvant therapies. I have spoken regionally, nationally, and internationally about utilizing neoadjuvant therapies in these circumstances. We have published extensively in this space, and much of our work has laid the foundation for many of the research ideas we are developing in the laboratory setting. This has culminated into the development of our Pancreas Cancer Translational Working Group, which is comprised of not only our physicians, but also our basic scientists, population scientists, and bioinformaticians. My most current project looks at the dynamic, reprogrammable patient secretomes measured directly from the tumor of interest. This sits squarely within this nexus of translational science at Fox Chase.
